Therefore, we conducted a single-center retrospective study to examine the characteristics of the bleeding events and compare the bleeding risk for two FXa inhibitor, rivaroxaban or edoxaban, in patients with respiratory diseases. This evidence concerns the gene F10 and respiratory system disorder.